TEAEs leading to ozanimod treatment withdrawal in the induction and maintenance periods included hemiplegia (1.5% [1/68]) in the ozanimod 0.46 mg group, macular edema (1.5% [1/65]) in the ozanimod 0.92 mg group, UC (2.9% [2/68]) in the ozanimod 0.46 mg group, drug-induced liver injury (1.5% [1/65]) in the ozanimod 0.92 mg group, pyrexia (1.5% [1/68]) in the ozanimod 0.46 mg group, alanine aminotransferase increased (3.1% [2/65]) in the ozanimod 0.92 mg group, and aspartate aminotransferase increased (3.1% [2/65]) in the ozanimod 0.92 mg group. Here, GPT is linked to macular retinal edema.